Pharma BD Deal Intelligence
Lilly CEO John Lechleiter framed Avid as aligning with the company's 'innovation-based strategy' with 'near-term revenue opportunity' — the $300M upfront /…
Amyloid PET adoption — Amyvid, Vizamyl (GE), Neuraceq (Life Molecular Imaging) — was reignited by anti-amyloid mAbs requiring biomarker-confirmed AD; the…
Avid's image-to-autopsy validation showed 34 of 35 florbetapir PET scans matched postmortem amyloid findings — the data backbone for a January 2011 unanimous…
Source summaries from our enrichment pipeline; follow links for originals.
All 5 sources with sentiment breakdown →
Lilly to acquire Avid Radiopharmaceuticals for $300M upfront + up to $500M regulatory/commercial milestones. Florbetapir later approved as Amyvid (2012).
Assessment window: 5yr post-close.
| Deal | Year | Value | Outcome |
|---|---|---|---|
| Eli Lilly and Company / Avid Radiopharmaceuticals, Inc. (this deal) | 2010 | $800M | 53 |
| Eli Lilly and Company / Boehringer Ingelheim GmbH | 2011 | $444M | 89 |
| Eli Lilly and Company / Loxo Oncology, Inc. | 2019 | $8.0B | 88 |
| Eli Lilly and Company / Applied Molecular Evolution Inc. | 2003 | $400M | 88 |
| Eli Lilly and Company / ICOS Corporation | 2006 | $2.3B | 87 |
| Eli Lilly and Company / Novartis Animal Health | 2014 | $5.4B | 70 |
| Eli Lilly and Company / Incyte Corporation | 2009 | $755M | 69 |
← Browse all deals · How we score deals
More: 2010 deals · Eli Lilly and Company deals · Neurology deals